About Us
  Career Opportunities

February 15, 2012
BioHelix Beverly Massachusetts Facility Earn ISO 13485:2003 Certification.
February 15, 2012
BioHelix Awarded a SBIR Grant to Develop a Cost-effective HIV Viral Load Assay.
October 17, 2011
BioHelix’s IsoAmp® HSV Assay Receives FDA Clearance for the Detection of Herpes Simplex Virus in Genital and Oral Lesions.
October 14, 2011
BioHelix Wins STTR Grant to Develop Point-of-Care Integrated MDx Platform with Boston University.
July 7, 2011
BioHelix announces FDA 510(k) submission of IsoAmp HSV Assay for detection of Herpes Simplex Virus in genital and oral lesions.
March 29, 2011
BioHelix is conducting clinical trials with its first in vitro diagnostic product, the IsoAmp® HSV assay.
March 29, 2011
BioHelix Awarded NIH Research Grant for Rapid Diagnostic Testing Of Malaria
October 6, 2009
Quidel and BioHelix enter into a joint development and commercialization agreement.
May 12, 2009
BioHelix has appointed Dr. Heiner Dreismann to its Board of Directors.
May 12, 2009
BioHelix Corporation has obtained a Cooperative Agreement and a Phase II SBIR Award from the NIAID for the development of diagnostic assays for CT/NG and HIV.
April 30, 2008
QIAGEN and BioHelix enter into licensing agreement.

April 3, 2008
BioHelix Corporation was awarded three NIH grants to develop diagnostic assays based on its proprietary HDA technologies.
March 12, 2007
BioHelix Corporation receives contract from the Department of Homeland Security to develop Next-Generation Molecular Diagnostics.
April 24, 2006
Whole Genome Amplification licensing agreement with Harvard University
June 16, 2005
BioHelix Corporation receives award from the Department of Homeland Security to develop portable diagnostic tools.

May 12, 2005
BioHelix Corporation launched IsoAmp® tHDA Kit.

March 16, 2005
BioHelix Corporation was awarded two NIH grants to develop new HDA technologies.

Privacy, Limitation, Warranty, Disclaimer